Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXSNASDAQ:EPIXNASDAQ:KODNASDAQ:THRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.36+3.1%$2.34$1.90▼$6.08$189.71M2.52716,946 shs528,934 shsEPIXESSA Pharma$1.72-0.6%$1.71$1.40▼$7.88$76.79M1.59339,135 shs164,976 shsKODKodiak Sciences$3.63+0.3%$3.76$1.92▼$11.60$191.01M2.27349,278 shs205,700 shsTHRXTheseus Pharmaceuticals$4.06$4.06$2.05▼$12.37$179.57M3.98592,167 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+3.06%+5.36%-1.67%-19.73%-19.73%EPIXESSA Pharma-0.58%+1.18%+1.78%+10.97%-64.90%KODKodiak Sciences+0.28%-2.94%+5.52%+13.44%+37.50%THRXTheseus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXSCodexis3.8283 of 5 stars3.33.00.02.52.71.70.6EPIXESSA Pharma1.6924 of 5 stars2.03.00.00.01.52.51.3KODKodiak Sciences4.238 of 5 stars3.04.00.04.62.53.30.0THRXTheseus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXSCodexis 2.50Moderate Buy$11.00366.10% UpsideEPIXESSA Pharma 2.00Hold$2.0016.28% UpsideKODKodiak Sciences 2.00Hold$9.00147.93% UpsideTHRXTheseus Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CDXS, THRX, KOD, and EPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXSCodexis$59.35M3.29N/AN/A$0.82 per share2.88EPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/AKODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ATHRXTheseus PharmaceuticalsN/AN/AN/AN/A$5.36 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXSCodexis-$65.28M-$0.99N/AN/AN/A-149.47%-118.47%-53.37%8/6/2025 (Estimated)EPIXESSA Pharma-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)THRXTheseus Pharmaceuticals-$50.61M-$1.34N/AN/AN/AN/A-24.84%-23.64%N/ALatest CDXS, THRX, KOD, and EPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CDXSCodexis-$0.20-$0.25-$0.05-$0.25$10.38 million$7.54 million5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/8/2025Q2 2025EPIXESSA Pharma-$0.19-$0.14+$0.05-$0.14N/AN/A3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXSCodexisN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ATHRXTheseus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXSCodexis0.593.723.64EPIXESSA PharmaN/A67.1567.15KODKodiak SciencesN/A4.624.62THRXTheseus PharmaceuticalsN/A29.9329.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXSCodexis78.54%EPIXESSA Pharma75.12%KODKodiak Sciences89.06%THRXTheseus Pharmaceuticals91.05%Insider OwnershipCompanyInsider OwnershipCDXSCodexis2.10%EPIXESSA Pharma15.50%KODKodiak Sciences45.90%THRXTheseus Pharmaceuticals46.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXSCodexis25082.85 million81.11 millionOptionableEPIXESSA Pharma5044.39 million37.51 millionOptionableKODKodiak Sciences9052.76 million28.55 millionOptionableTHRXTheseus Pharmaceuticals3844.23 million23.58 millionOptionableCDXS, THRX, KOD, and EPIX HeadlinesRecent News About These CompaniesThe True Cost of LayoffsAugust 9, 2024 | bloomberg.comKS2 / KS3 English: A Midsummer Night's Dream. 1: Welcome to AthensMay 20, 2024 | bbc.co.ukTheseus Pharmaceuticals Announces Closing of Tender OfferFebruary 14, 2024 | finance.yahoo.comTheseus Pharmaceuticals Announces Closing of Tender OfferFebruary 14, 2024 | prnewswire.comConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsJanuary 30, 2024 | finance.yahoo.comSHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, THRX, GRCL, ROVRJanuary 20, 2024 | stockhouse.comTheseus Pharmaceuticals Inc [THRX] Investment Guide: What You Need to KnowJanuary 1, 2024 | knoxdaily.comTHESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...December 31, 2023 | businesswire.comIs Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?December 29, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSKE, KRTX, THRX, CONNDecember 27, 2023 | markets.businessinsider.comTheseus Pharmaceuticals Shares Rise 9.3% on Deal to Be Acquired by ConcentraDecember 22, 2023 | marketwatch.comConcentra Biosciences to Acquire Theseus Pharmaceuticals for $3.90 to $4.05/ShrDecember 22, 2023 | marketwatch.comTheseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In CashDecember 22, 2023 | markets.businessinsider.comTHRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Theseus Pharmaceuticals, Inc. Is Fair to ShareholdersDecember 22, 2023 | tmcnet.comTheseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightDecember 22, 2023 | finance.yahoo.comUP Fintech, Cerence, Irsa Inversiones Y Representaciones among premarket gainers packNovember 27, 2023 | msn.comTheseus Pharma To Evaluate Expression Of Interest From Foresite, OrbiM And Proposal From ConcentraNovember 27, 2023 | markets.businessinsider.comTheseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCNovember 27, 2023 | finance.yahoo.comTheseus Pharmaceuticals Laying Off 72 Percent of WorkforceNovember 15, 2023 | precisionmedicineonline.comWell-funded Theseus takes bold action for a fresh startNovember 15, 2023 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDXS, THRX, KOD, and EPIX Company DescriptionsCodexis NASDAQ:CDXS$2.36 +0.07 (+3.06%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.36 0.00 (-0.21%) As of 06/23/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.ESSA Pharma NASDAQ:EPIX$1.72 -0.01 (-0.58%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.72 0.00 (0.00%) As of 06/23/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Kodiak Sciences NASDAQ:KOD$3.63 +0.01 (+0.28%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$3.63 0.00 (0.00%) As of 06/23/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Theseus Pharmaceuticals NASDAQ:THRXTheseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
